butabarbital decreases consequences of sufentanil SL by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Closely. Coadministration of CYP3A4 inducers may possibly minimize sufentanil amounts and efficacy, quite possibly precipitating withdrawal syndrome in clients who have developed Actual physical dependence to sufenta